Ansell share price set to benefit from coronavirus stockpiling

As grim as it seems, some companies stand to benefit from coronavirus stockpiling. Here's why Ansell Limited (ASX:ANN) may be one of them.

As grim as it seems, some companies stand to benefit from coronavirus stockpiling. In fact, facing threats like this is part of some companies' business models.

Ansell Limited (ASX: ANN) produces face masks, protective gloves, respirators and many other physical protection devices for industry and healthcare use. All of these are currently subject to stockpiling for coronavirus; an issue that may impact many of us. 

The Ansell share price fell 6% last week on the back of coronavirus fears. At the time of writing, Ansell shares have fallen another 1.18% today and are presently trading at $29.25 with a price to earnings (P/E) multiple of 17.8.

In the company's 1H20 earnings report, Ansell showed a lift in adjusted earnings before interest and tax (EBIT) by 4.8% against the previous corresponding period (pcp) and an 8.7% pcp increase in adjusted earnings per share (EPS).

The H1 report also called out the company's role in supplying personal protective equipment (PPE). In particular in China where Ansell is working with authorities to fast track its regulatory and import process in order to expedite supply.

Last Friday onn February 28, the company announced it had purchased more shares in its ongoing share buyback program which will add additional value to shareholders and boost EPS.

Over the past ten years, Ansell has demonstrated strong and consistent management in the PPE space. The Ansell share price has grown at a compound annual growth rate (CAGR) of 12% even though EPS has a 10-year CAGR of only 6.2%.

a woman

Stockpiling for coronavirus

Friday's Canberra Times article spoke of surgical masks being restricted at Brisbane airport due to limited supply. Even as early as the beginning of February, doctors were admonishing the public for stockpiling things like surgical masks.

These products are likely to face extra demand as long as coronavirus stockpiling continues. With the tragic fatality in Perth this weekend and the reports of stockpiling for coronavirus globally, I believe that the trend will continue. 

Foolish takeaway

During global health events, companies like Ansell are part of the emergency response team. These companies are built partly to fulfill the need that epidemic (and pandemic) scares like this create.

Given the global trend of stockpiling for coronavirus, Ansell is already coming under pressure to manufacture PPE for health workers and will likely see earnings per share increase regardless of any share buybacks. 

Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Why are Mesoblast shares racing 15% higher today?

Find out what caught investor interest.

Read more »

Happy doctor using her laptop.
Healthcare Shares

Should I buy Cochlear and Mesoblast shares with $5,000?

These two companies are at different stages of their growth journeys. Here's which I'd choose for a long-term investment.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city.
Healthcare Shares

Are ResMed shares a strong buy before its results on Friday?

Here's my verdict on whether I'd buy shares before the announcement.

Read more »

A doctor looks unsure.
Healthcare Shares

Could CSL shares smash past $200 in the next 12 months?

Are CSL shares a buy, sell, or hold now?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 ASX 200 healthcare shares to buy with 35% to 103% upside ahead

Are any of these ASX shares in your portfolio?

Read more »